Dr. Renato Martins on the Effects of Nivolumab and Ipilimumab

Video

Dr. Renato G. Martins talks about the impact of nivolumab, an anti–PD-1, and ipilimumab, an anti CTLA-4, in the treatment of lung cancer.

Renato G. Martins, MD, MPH, medical director, Thoracic/Head and Neck Medical Oncology, Seattle Cancer Care Alliance, Fred Hutch Professor, University of Washington School of Medicine, discusses the impact of nivolumab, an anti—PD-1, and ipilimumab, an anti–CTLA-4, in the treatment of lung cancer.

Martins says there are patients who were treated with nivolumab and ipilimumab years ago that have not had a recurrence of lung cancer. He says the effects of nivolumab and ipilimumab are “unprecedented” and that the combination of the positive side effect profile and the quality of the responses have made medical professionals particularly enthusiastic.

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center